- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07938814
A Phase I/II, Dose-Escalation and Dose-Expansion Study of CS5006, in Participants With Advanced Solid Tumors
A Phase I/II, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activities of CS5006, a Novel Antibody-Drug Conjugate Targeting ITGB4, in Participants With Advanced Solid Tumors
This is a first-in-human (FIH), open-label, and multi-center Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5006 in participants with advanced solid tumors. The study comprises of a Phase I dose escalation and Phase II dose expansion.
Обзор исследования
Подробное описание
In Phase I, participants with specified advanced epithelial solid tumors will be enrolled to establish the MTD, if any, and tentative RP2D(s) of CS5006. The specified advanced epithelial solid tumors included but not limited non-small cell lung cancer (NSCLC), colorectal cancer (CRC), squamous cell carcinoma of head and neck (HNSCC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), cervical cancer (CC), esophageal squamous cell carcinoma (ESCC) , endometrial cancer, ovarian cancer (OC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), biliary tract cancer (BTC), gastric cancer (GC), pancreatic cancer(PDAC) and prostate cancer(PCa).
In Phase II, participants with selected advanced solid tumors - including locally advanced or metastatic non-small cell lung cancers (AGA [actionable genomic alterations] negative NSCLC, Cohort 1; EGFR-mutant NSCLC, Cohort 2; NSCLC with actionable driver alterations other than EGFR-sensitive mutations, Cohort 3; colorectal cancer (CRC), Cohort 4; squamous cell carcinoma of head and neck (HNSCC), Cohort 5; urothelial carcinoma (UC), Cohort 6; cervical cancer (CC), Cohort 7; esophageal squamous cell carcinoma (ESCC), Cohort 8 - will be enrolled to further assess the efficacy, safety, tolerability, pharmacokinetics of CS5006 at the tentative RP2D(s).
Тип исследования
Регистрация (Оцененный)
Фаза
- Фаза 2
- Фаза 1
Контакты и местонахождение
Контакты исследования
- Имя: Crystal Wang
- Номер телефона: +86-021-60332455
- Электронная почта: wangjingru@cstonepharma.com
Места учебы
-
-
New South Wales
-
North Ryde, New South Wales, Австралия, 2109
- Macquarie University
-
Главный следователь:
- John Park, Dr
-
Randwick, New South Wales, Австралия, 2031
- Scientia Clinical Research Ltd
-
Главный следователь:
- Charlotte lemech, Dr
-
-
Victoria
-
Clayton, Victoria, Австралия, 3168
- Monash Medical Centre
-
Главный следователь:
- Sophia Frentzas, Dr
-
-
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Китай, 200123
- Shanghai East Hospital
-
Главный следователь:
- Caicun Zhou
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent document.
- Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- Being ≥ 18 years of age on the day of signing informed consent.
- Pathologically or cytologically confirmed, unresectable advanced solid tumors.
- Participants must have at least one measurable lesion according to RECIST Version1.1.
- Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1.
- Adequate organ function.
- Life expectancy ≥ 3 months.
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 180 days after the last study drug administration
Exclusion Criteria:
- Has disease that is suitable for local treatment administered with curative intent.
- Has a history of a second malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured.
- Known primary central nervous system (CNS) tumor or solid tumor CNS metastasis that is symptomatic, untreated, or requires therapy.
- Has life-threatening bleeding event or severe bleeding within 3 months prior to first dose.
- Has uncontrolled pleural effusion, pericardial effusion, or ascites.
- Has immune deficient disease or received systemic immunosuppressive treatment.
- Has intestinal obstruction,or history of inflammatory bowel disease,or chronic diarrhea.
- Has history of (non-infectious) interstitial lung disease/pneumonitis that required steroids.
- Has active infections requiring systemic therapy.
- Has significant cardiovascular disease or cerebrovascular accident within specified timeframes prior to first dose.
- Insufficient washout from prior anti-tumor therapy.
- Received live vaccine within 28 days prior to first dose.
- History of allogeneic organ or hematopoietic stem cell transplantation.
- History of hypersensitivity to excipients of study drug or any monoclonal antibody.
- Any toxic effects of prior therapy unresolved to Grade ≤1.
- Pregnant or breastfeeding women.
- Other acute or chronic medical or psychiatric conditions that may increase risk or interfere with study results, in the investigator's judgment.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Dose Escalation
Participants will be administered escalating doses of CS5006. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
|
Экспериментальный: Dose Expansion
Participants will be administered the recommended dose(s) of CS5006 according to dose-escalation data. |
CS5006 will be administered via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
[Увеличение дозы] Частота объективного ответа (ЧОО), оцененная исследователями согласно RECIST v1.1
Временное ограничение: Примерно до 2 лет
|
Примерно до 2 лет
|
|
|
[Dose Escalation] The incidence and severity of adverse events (AEs)
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
|
[Dose Escalation] Maximum tolerated dose (MTD) of CS5006
Временное ограничение: Cycle 1 (Up to 21 Days)
|
Participants will receive CS5006 via intravenous (IV) infusion on Day 1 of repeated 21-day cycles (Q3W). The MTD will be determined, if any, by the number of participants who experience a dose limiting toxicity (DLT). |
Cycle 1 (Up to 21 Days)
|
|
[Dose Escalation] Tentative recommended Phase II dose (RP2D) of CS5006
Временное ограничение: Up to approximately 2 years
|
The selection of tentative RP2D will be based on consideration of overall safety information together with available pharmacokinetic, pharmacodynamic, and efficacy data. The tentative RP2D may be the MTD or a lower dose within the tolerable dose range. |
Up to approximately 2 years
|
Вторичные показатели результатов
Мера результата |
Временное ограничение |
|---|---|
|
[Эскалация дозы] Частота объективного ответа (ЧОО), оцененная исследователями согласно RECIST v1.1
Временное ограничение: Примерно до 2 лет
|
Примерно до 2 лет
|
|
[Dose Escalation & Expansion] Area under the curve (AUC) of CS5007
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Duration of response (DOR) evaluated by investigators per RECIST v1.1
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Disease control rate (DCR) evaluated by investigators per RECIST v1.1
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Expansion] The incidence and severity of adverse events (AEs)
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Maximum concentration (Cmax) of CS5006
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Time to maximum concentration (Tmax) of CS5006
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Elimination half-life (t1/2) of CS5006
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Clearance (CL) of CS5006
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Volume of distribution (Vz) of CS5006
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Trough concentration (Ctrough) of CS5006
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Accumulation ratio (R) of CS5006
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
|
[Dose Escalation & Expansion] Number of participants with anti-CS5006 antibodies
Временное ограничение: Up to approximately 2 years
|
Up to approximately 2 years
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Оцененный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Другие идентификационные номера исследования
- CS5006-101
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .